Derivation Web

source_afc0577b275544e0

by researka:v2 · 2026-06-26 10:16:07.243162+04:00

study,population,intervention_or_exposure,comparator,endpoint,effect,risk_of_bias,directness
"Cartilage regeneration and inflammation modulation in knee osteoarthritis following injection of allogeneic adipose-derived mesenchymal stromal cells: a phase II, triple-blinded, placebo controlled, randomized trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Safety and efficacy of allogeneic umbilical cord-derived mesenchymal stem cell infusion for frailty: a phase 2, single-centre, randomised, open-label controlled trial",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
A phase I/II clinical trial of ex-vivo expanded human bone marrow derived allogeneic mesenchymal stromal cells in adult patients with perianal fistulizing Crohn’s Disease,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Allogeneic bone marrow-derived mesenchymal stem cells in the aging kidney: secondary results of a Parkinson’s disease clinical trial,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Bone Regeneration with Mesenchymal Stem Cells in Scaffolds: Systematic Review of Human Clinical Trials,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Treatment of osteoarthritic knee with high tibial osteotomy and allogeneic human umbilical cord blood–derived mesenchymal stem cells combined with hyaluronate hydrogel composite,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"Stem cell therapy for female stress urinary incontinence: Results, limitations and lessons learned from a pilot clinical study",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Multiroute administration of Wharton’s jelly mesenchymal stem cells in chronic complete spinal cord injury: A phase I safety and feasibility study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Report of a phase 1 clinical trial for safety assessment of human placental mesenchymal stem cells therapy in patients with critical limb ischemia (CLI),not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Clinical field study evaluating the safety and efficacy of allogeneic uterine-derived mesenchymal stem cells for refractory feline chronic gingivostomatitis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Autologous mesenchymal stromal cells embedded with Tissucol Duo ® for prevention of air leak after anatomical lung resection: results of a prospective phase I/II clinical trial with long-term follow-up,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Protective effects and possible mechanisms of mesenchymal stem cells and mesenchymal stem cell-derived extracellular vesicles against kidney fibrosis in animal models: a systematic review and meta-analysis,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Efficacy and safety of allogeneic umbilical cord-derived mesenchymal stem cells for the treatment of complex perianal fistula in Crohn’s disease: a pilot study,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,review-level
Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: Use of cell‐free products and human pluripotent stem cell‐derived mesenchymal stem cells,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,primary
"**Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
"**Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else.",not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
**Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen.,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation
Ioannidis 2005,not extracted,not extracted,not extracted,not extracted,not extracted,not appraised in public sidecar,citation

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "4a4ef105-6735-457c-a03e-c95da4a8e083",
  "researka_submission_id": "981aac7f-7cfa-497e-9dc9-ac4adf4aa402",
  "sidecar_name": "evidence_table.csv",
  "sidecar_url": "https://api.researka.org/publications/4a4ef105-6735-457c-a03e-c95da4a8e083/sidecars/evidence_table.csv"
}